drugset / Trial / NCT05551013

Treatment of Recurrent GBM With APG-157 Via Expanded Access

NCT05551013 ↗

Expanded access No longer available Aveta Biomics, Inc.

Summary

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-157 Unknown — Oral

Indications